NX

Nexien Biopharma IncOOTC NXEN Stock Report

Last reporting period 31 Dec, 2023

Updated 14 Nov, 2024

Last price

Market cap $B

0.001

Micro

Exchange

OOTC - OTC

NXEN Stock Analysis

NX

Uncovered

Nexien Biopharma Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.001

Dividend yield

Shares outstanding

62.772 B

Nexien BioPharma, Inc. engages in the development and commercialization of Food and Drug Administration-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company is headquartered in Glendale, Colorado. The company went IPO on 2001-07-11. The firm is focused on developing and commercializing United States Food and Drug Administration (FDA) -compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The firm's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.

View Section: Eyestock Rating